Ilona Telefus Goldfarb, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pregnancy Complications, Infectious | 15 | 2022 | 2151 | 2.210 |
Why?
|
Pregnant Women | 6 | 2021 | 561 | 1.180 |
Why?
|
Placenta | 9 | 2024 | 1704 | 0.920 |
Why?
|
Postpartum Period | 5 | 2022 | 1172 | 0.870 |
Why?
|
Pregnancy | 39 | 2024 | 29831 | 0.860 |
Why?
|
Placenta Diseases | 2 | 2022 | 196 | 0.800 |
Why?
|
Abruptio Placentae | 2 | 2020 | 118 | 0.780 |
Why?
|
Influenza Vaccines | 3 | 2023 | 763 | 0.730 |
Why?
|
Parturition | 3 | 2022 | 445 | 0.730 |
Why?
|
Infant, Small for Gestational Age | 2 | 2019 | 461 | 0.680 |
Why?
|
Pregnancy Trimester, Third | 2 | 2021 | 583 | 0.660 |
Why?
|
Pregnancy Trimester, First | 3 | 2022 | 907 | 0.650 |
Why?
|
Vaccination | 8 | 2023 | 3375 | 0.640 |
Why?
|
Stillbirth | 2 | 2022 | 368 | 0.630 |
Why?
|
Purpura, Thrombotic Thrombocytopenic | 1 | 2020 | 130 | 0.630 |
Why?
|
Fetus | 4 | 2021 | 1863 | 0.620 |
Why?
|
Pregnancy Complications, Hematologic | 1 | 2020 | 179 | 0.620 |
Why?
|
Inservice Training | 1 | 2019 | 375 | 0.550 |
Why?
|
Aneuploidy | 2 | 2019 | 551 | 0.540 |
Why?
|
Toll-Like Receptor 9 | 1 | 2017 | 233 | 0.530 |
Why?
|
Diphtheria-Tetanus-acellular Pertussis Vaccines | 2 | 2023 | 38 | 0.500 |
Why?
|
Decision Making | 2 | 2020 | 3923 | 0.490 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 747 | 0.480 |
Why?
|
Patient Acceptance of Health Care | 3 | 2020 | 3190 | 0.470 |
Why?
|
Mass Screening | 2 | 2020 | 5424 | 0.430 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3080 | 0.410 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3200 | 0.410 |
Why?
|
Pandemics | 10 | 2023 | 8623 | 0.340 |
Why?
|
Infectious Disease Transmission, Vertical | 4 | 2021 | 1351 | 0.280 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2011 | 445 | 0.280 |
Why?
|
Curriculum | 2 | 2021 | 3732 | 0.270 |
Why?
|
Massachusetts | 6 | 2023 | 8826 | 0.240 |
Why?
|
Pemphigoid Gestationis | 1 | 2024 | 5 | 0.240 |
Why?
|
Female | 39 | 2024 | 391875 | 0.240 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7996 | 0.230 |
Why?
|
Gynecology | 2 | 2021 | 526 | 0.230 |
Why?
|
Quality Improvement | 1 | 2019 | 3798 | 0.230 |
Why?
|
Adenosine Monophosphate | 2 | 2022 | 230 | 0.230 |
Why?
|
Infant, Newborn | 12 | 2023 | 26280 | 0.230 |
Why?
|
DNA | 1 | 2017 | 7208 | 0.220 |
Why?
|
Obstetrics | 2 | 2021 | 665 | 0.210 |
Why?
|
Fetal Research | 1 | 2021 | 6 | 0.200 |
Why?
|
Influenza, Human | 2 | 2023 | 1517 | 0.190 |
Why?
|
Premature Birth | 4 | 2023 | 1780 | 0.190 |
Why?
|
Peripartum Period | 1 | 2022 | 137 | 0.180 |
Why?
|
Practice Guidelines as Topic | 1 | 2017 | 7380 | 0.180 |
Why?
|
Interleukin-10 Receptor beta Subunit | 1 | 2020 | 15 | 0.180 |
Why?
|
Interleukin-10 Receptor alpha Subunit | 1 | 2020 | 28 | 0.170 |
Why?
|
Humans | 40 | 2024 | 760437 | 0.170 |
Why?
|
Anesthesia, Spinal | 1 | 2022 | 280 | 0.170 |
Why?
|
Hematoma | 2 | 2022 | 768 | 0.170 |
Why?
|
Plasma Exchange | 1 | 2020 | 158 | 0.170 |
Why?
|
Asymptomatic Infections | 1 | 2020 | 131 | 0.170 |
Why?
|
Fetal Death | 1 | 2021 | 435 | 0.160 |
Why?
|
Internship and Residency | 1 | 2019 | 5866 | 0.160 |
Why?
|
Lacerations | 1 | 2020 | 147 | 0.160 |
Why?
|
Boston | 3 | 2020 | 9326 | 0.160 |
Why?
|
Maternal-Fetal Exchange | 1 | 2020 | 462 | 0.160 |
Why?
|
Wireless Technology | 2 | 2016 | 98 | 0.150 |
Why?
|
Infant, Low Birth Weight | 2 | 2021 | 868 | 0.150 |
Why?
|
Obstetric Labor Complications | 1 | 2020 | 236 | 0.150 |
Why?
|
Adult | 19 | 2024 | 220781 | 0.150 |
Why?
|
Immunoglobulin G | 2 | 2020 | 4549 | 0.150 |
Why?
|
Inflammation | 1 | 2017 | 10746 | 0.150 |
Why?
|
Feedback | 1 | 2021 | 791 | 0.140 |
Why?
|
Delivery, Obstetric | 2 | 2021 | 940 | 0.140 |
Why?
|
Hypertension, Pregnancy-Induced | 2 | 2019 | 517 | 0.140 |
Why?
|
Hypotension | 1 | 2022 | 879 | 0.140 |
Why?
|
Pregnancy Outcome | 4 | 2021 | 2916 | 0.140 |
Why?
|
Chorionic Villi Sampling | 1 | 2016 | 35 | 0.140 |
Why?
|
Interviews as Topic | 2 | 2021 | 2683 | 0.130 |
Why?
|
Amniocentesis | 1 | 2016 | 115 | 0.130 |
Why?
|
Professional Competence | 1 | 2019 | 431 | 0.130 |
Why?
|
Fetal Growth Retardation | 1 | 2019 | 579 | 0.130 |
Why?
|
Progesterone | 1 | 2020 | 742 | 0.130 |
Why?
|
Receptors, Fc | 1 | 2019 | 535 | 0.130 |
Why?
|
Infant, Newborn, Diseases | 1 | 2021 | 591 | 0.130 |
Why?
|
Continuity of Patient Care | 1 | 2022 | 1069 | 0.130 |
Why?
|
Remote Sensing Technology | 1 | 2016 | 92 | 0.120 |
Why?
|
Viral Vaccines | 1 | 2020 | 596 | 0.120 |
Why?
|
Prevalence | 3 | 2021 | 15698 | 0.120 |
Why?
|
Cardiotocography | 1 | 2015 | 24 | 0.120 |
Why?
|
Vital Signs | 1 | 2016 | 144 | 0.120 |
Why?
|
Clinical Clerkship | 1 | 2021 | 564 | 0.120 |
Why?
|
Efficiency, Organizational | 1 | 2019 | 695 | 0.120 |
Why?
|
Interleukin-10 | 1 | 2020 | 1176 | 0.120 |
Why?
|
Chromosome Disorders | 1 | 2016 | 499 | 0.110 |
Why?
|
Microarray Analysis | 1 | 2016 | 748 | 0.110 |
Why?
|
Antibodies, Viral | 2 | 2022 | 3155 | 0.110 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2019 | 1355 | 0.100 |
Why?
|
Polysaccharides | 1 | 2019 | 1014 | 0.100 |
Why?
|
Epidemics | 1 | 2017 | 512 | 0.100 |
Why?
|
Vaccines | 1 | 2020 | 836 | 0.100 |
Why?
|
Cesarean Section | 1 | 2020 | 1393 | 0.090 |
Why?
|
Telomere | 1 | 2017 | 931 | 0.090 |
Why?
|
Retrospective Studies | 11 | 2023 | 80430 | 0.090 |
Why?
|
Prenatal Care | 1 | 2018 | 1134 | 0.090 |
Why?
|
Oseltamivir | 1 | 2011 | 75 | 0.090 |
Why?
|
Cause of Death | 1 | 2021 | 3686 | 0.090 |
Why?
|
Cardiomyopathies | 1 | 2022 | 1957 | 0.090 |
Why?
|
United States | 8 | 2022 | 72202 | 0.080 |
Why?
|
Hospitals | 2 | 2021 | 3873 | 0.080 |
Why?
|
Guideline Adherence | 1 | 2019 | 2215 | 0.080 |
Why?
|
Feasibility Studies | 1 | 2019 | 5236 | 0.080 |
Why?
|
Thrombosis | 1 | 2022 | 2940 | 0.070 |
Why?
|
Treatment Refusal | 1 | 2011 | 429 | 0.070 |
Why?
|
Interleukin-6 | 1 | 2017 | 3209 | 0.070 |
Why?
|
Risk | 1 | 2019 | 9605 | 0.070 |
Why?
|
Receptors, IgG | 2 | 2020 | 559 | 0.070 |
Why?
|
Logistic Models | 3 | 2019 | 13240 | 0.070 |
Why?
|
Patient Satisfaction | 2 | 2016 | 3457 | 0.070 |
Why?
|
Safety | 1 | 2011 | 1150 | 0.070 |
Why?
|
Young Adult | 7 | 2021 | 59068 | 0.070 |
Why?
|
Sepsis | 1 | 2019 | 2583 | 0.060 |
Why?
|
Seasons | 1 | 2011 | 1518 | 0.060 |
Why?
|
Whooping Cough | 1 | 2023 | 86 | 0.050 |
Why?
|
Macrophages | 1 | 2017 | 5764 | 0.050 |
Why?
|
Compassionate Use Trials | 1 | 2021 | 50 | 0.050 |
Why?
|
Labor Stage, Second | 1 | 2020 | 37 | 0.040 |
Why?
|
Health Services Accessibility | 1 | 2017 | 5421 | 0.040 |
Why?
|
Case-Control Studies | 3 | 2022 | 22097 | 0.040 |
Why?
|
Belgium | 1 | 2019 | 117 | 0.040 |
Why?
|
Alanine | 1 | 2021 | 606 | 0.040 |
Why?
|
Prospective Studies | 2 | 2021 | 54339 | 0.040 |
Why?
|
Risk Assessment | 1 | 2020 | 23953 | 0.040 |
Why?
|
Cohort Studies | 3 | 2019 | 41366 | 0.040 |
Why?
|
Cell Degranulation | 1 | 2019 | 276 | 0.040 |
Why?
|
Antiviral Agents | 1 | 2011 | 3066 | 0.040 |
Why?
|
Anal Canal | 1 | 2020 | 373 | 0.040 |
Why?
|
Policy | 1 | 2021 | 508 | 0.040 |
Why?
|
Socioeconomic Factors | 2 | 2021 | 7817 | 0.030 |
Why?
|
Chorioamnionitis | 1 | 2017 | 156 | 0.030 |
Why?
|
Immunity | 1 | 2022 | 997 | 0.030 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2011 | 3996 | 0.030 |
Why?
|
Glycosylation | 1 | 2019 | 1097 | 0.030 |
Why?
|
Uterus | 1 | 2020 | 649 | 0.030 |
Why?
|
Uterine Hemorrhage | 1 | 2017 | 240 | 0.030 |
Why?
|
Abortion, Induced | 1 | 2021 | 462 | 0.030 |
Why?
|
Informed Consent | 1 | 2021 | 1006 | 0.030 |
Why?
|
Heart Rate, Fetal | 1 | 2015 | 75 | 0.030 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2022 | 1715 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12054 | 0.030 |
Why?
|
Maternal Age | 1 | 2016 | 809 | 0.030 |
Why?
|
Community Health Centers | 1 | 2016 | 460 | 0.030 |
Why?
|
Hemodynamics | 1 | 2022 | 4167 | 0.030 |
Why?
|
Gestational Age | 1 | 2021 | 3574 | 0.020 |
Why?
|
Birth Weight | 1 | 2019 | 2098 | 0.020 |
Why?
|
Qualitative Research | 1 | 2021 | 3008 | 0.020 |
Why?
|
Mice | 1 | 2017 | 81402 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2019 | 2202 | 0.020 |
Why?
|
Infant | 2 | 2021 | 36183 | 0.020 |
Why?
|
Animals | 2 | 2020 | 168253 | 0.020 |
Why?
|
Prenatal Diagnosis | 1 | 2016 | 1265 | 0.020 |
Why?
|
Adolescent | 4 | 2019 | 88196 | 0.020 |
Why?
|
Risk Factors | 3 | 2021 | 74055 | 0.020 |
Why?
|
Lymphocyte Activation | 1 | 2019 | 5491 | 0.020 |
Why?
|
Linear Models | 1 | 2017 | 5865 | 0.020 |
Why?
|
Language | 1 | 2016 | 1537 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7230 | 0.020 |
Why?
|
Biopsy | 1 | 2017 | 6765 | 0.020 |
Why?
|
Cross-Sectional Studies | 2 | 2016 | 26063 | 0.010 |
Why?
|
Male | 4 | 2022 | 360035 | 0.010 |
Why?
|
Pilot Projects | 1 | 2015 | 8611 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 22121 | 0.010 |
Why?
|
Obesity | 1 | 2023 | 12918 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 15257 | 0.010 |
Why?
|
Hospitalization | 1 | 2021 | 10698 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13484 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2017 | 20078 | 0.010 |
Why?
|
Time Factors | 1 | 2017 | 39947 | 0.010 |
Why?
|
Middle Aged | 2 | 2021 | 220382 | 0.010 |
Why?
|